Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | BRAF |
Variant | class 1 |
Impact List | unknown |
Protein Effect | gain of function |
Gene Variant Descriptions | BRAF Class 1 variants are BRAF variants that activate BRAF and downstream signaling in a dimer-independent, RAS-independent manner (PMID: 28783719, PMID: 26343582). |
Associated Drug Resistance | |
Category Variants Paths |
BRAF mutant BRAF act mut BRAF class 1 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04916236 | Phase I | LY3214996 + RMC-4630 | Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers (SHERPA) | Unknown status | NLD | 0 |
NCT06208124 | Phase Ib/II | IMM-6-415 | A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors | Recruiting | USA | 0 |
NCT06270082 | Phase I | IK-595 | Study of IK-595 in RAS- or RAF-altered Advanced Tumors | Recruiting | USA | 0 |
NCT05786924 | Phase I | BDTX-4933 | A Study of BDTX-4933 in Patients With KRAS, BRAF and Select RAS/MAPK Mutation-Positive Cancers | Active, not recruiting | USA | 0 |
NCT05512208 | Phase II | Defactinib + RO5126766 | A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib (DURAFAK) | Recruiting | USA | 0 |
NCT04913285 | Phase I | Binimetinib + Exarafenib Exarafenib | A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors | Recruiting | USA | NLD | FRA | ESP | AUS | 3 |